Thanks for your comments -- and I agree, the information we have about medications on the market or in development is primitive at best. Alzheimer's Disease is showing all the characteristics of a disease that will eventually be treated din a variety of ways depending on patient response and will eventually require "cocktails" of treatments depending on the patients' genetic make up, their symptoms, the progression of the disease and the expertise of the treating physician.

That being said, the issue for an investor in Neurochem is not what we believe but how the FDA is going to view the trial data - is the data compelling enough to warrant an approval? I recommended NRMX long ago, then told readers to walk away with a tidy profit because there was too much ambiguity in the data. I believe the company moved forward with trials trying to show efficacy equal to or better than existing, reasonably INEFFECTIVE treatments, and the bar has move don them as the medical community and insurance companies are increasingly skeptical about the approved treatments on the market.

We shall see -- thanks again for your comments.